The Fresh Market Donates More Than $21,000 in Support of the Alzheimer's Association
Throughout the month of June, the premium grocery retailer pledged to donate 10 percent of the sales price of Carla Hall's Sweet Heritage Butter Tarts to the Alzheimer's Association.
Throughout the month of June, the premium grocery retailer pledged to donate 10 percent of the sales price of Carla Hall's Sweet Heritage Butter Tarts to the Alzheimer's Association. The campaign aimed to raise awareness and fund critical research toward a cure. In total, The Fresh Market contributed $21,541.70 to the organization.
'It was our pleasure to partner with Carla Hall to help raise awareness and support for the millions of Americans living with Alzheimer's disease,' said Emily Turner, chief marketing officer at The Fresh Market. 'This cause is close to our hearts at The Fresh Market, and we're incredibly grateful to the Alzheimer's Association, Carla Hall, and—most importantly—our guests for helping us reach our fundraising goals.'
'We're grateful to The Fresh Market and Carla Hall for their commitment to the fight to end Alzheimer's and all other dementia,' said Sarah Fried, vice president, corporate initiatives, Alzheimer's Association. 'Alzheimer's impacts millions of families and partnerships like this help fund critical care and support services and disease research, while spurring important conversation and encouraging others to join us in the fight to end this disease.'
Carla Hall—known for her appearances on Bravo, Food Network, and ABC —is a passionate advocate for individuals living with Alzheimer's disease and a longtime supporter of the Alzheimer's Association. Her advocacy is deeply personal, inspired by her grandmother's experience with the disease.
'A big ol' thank you to everyone who stopped by The Fresh Market and picked up my Sweet Heritage Butter Tarts!' said Carla Hall. 'Y'all didn't just treat yourselves — you helped raise more than $21,000 for the Alzheimer's Association!
'That's a whole lot of goodness doing double duty: satisfying your sweet tooth and supporting critical research to help us get closer to a cure. I'm so proud to be part of this delicious way to give back. Let's keep showing up for each other and keep working to #ENDALZ — one bite at a time!'
The number of Americans living with Alzheimer's is growing — and growing fast. According to the Alzheimer's Association's 2025 Facts and Figures report, nearly 7 million Americans are living with Alzheimer's and it is estimated that more than half of all Americans know someone with the disease. Additionally, almost 12 million family members and friends serve as dementia caregivers.
About The Fresh Market
Rated by USA Today as one of America's Best Customer Service Companies in 2025, voted #1 in three categories by USA Today's 10Best Readers' Choice Awards for 2024—"Best Grocery Store Bakery," "Best Grocery Store Deli," and "Best Grocery Store Prepared Foods"—and recognized for three consecutive years as the 'Best Grocery Store in America.' The Fresh Market currently operates more than 170 grocery stores in 22 states across the U.S. and one Spirits & Wine store, inspiring guests to discover new flavors and cook with confidence. For more information, please visit www.thefreshmarket.com or follow the company on Facebook, Instagram, TikTok, X and Pinterest.
About the Alzheimer's Association
The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
About Carla Hall
Chef, best-selling author and television personality Carla Hall has been entertaining audiences with her enthusiasm for life and warm personality for years. She has starred on Food Network shows such as 'BakeAway Camp,' 'Halloween Baking Championship,' 'Holiday Baking Championship' and 'Worst Cooks in America.' She also hosted the Emmy-nominated 'Chasing Flavor with Carla Hall' (HBO Max) and serves as a judge on 'Harry Potter: Wizards of Baking' (HBO Max). She first won over audiences when she competed on Bravo's 'Top Chef' and hosted ABC's 'The Chew' for 7 years.
Her product line, Sweet Heritage by Carla Hall (available through QVC), is designed to bring you kitchen items that are useful, reliable, and complete with a dash of joy and soul. Carla's latest cookbook, Carla Hall's Soul Food: Everyday and Celebration, was published in 2018, landing on annual "Best Cookbook" lists across the country and receiving an NAACP Image Awards nomination. Her second children's book, Carla and the Tin Can Cake Party will be published October 14th.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
17 minutes ago
- USA Today
Family of boy who died from brain-eating amoeba speaks out: 'Unimaginable'
The family of a 12-year-old boy from South Carolina is grieving after he died from a brain-eating amoeba, according to a statement from their lawyer. Jaysen Carr died on July 18 after developing an infection from the brain-eating amoeba Naegleria fowleri, the statement shared by Bailey Law Firm said. The South Carolina Department of Public Health confirmed in a statement to USA TODAY on July 23 that a person died after being exposed to the amoeba earlier in July. Prisma Health Children's Hospital Midlands confirmed on July 22 that the person was treated at the facility but did not publicly identify the person. "The Carr family is incredibly grateful for the outpouring of love from the community and for the dedicated care provided by the doctors and nurses at Prisma Health Children's Hospital in the Midlands," the statement said. Brain-eating amoeba victim was 'bright and beloved' middle schooler The statement from the Carr family's lawyer said Jaysen was a "bright and beloved" middle school student. "His loss is unimaginable, and our hearts are with his family as they grieve their son and search for answers," the statement said. The legal team said it will "stand beside this family not only to seek the truth, but to help ensure no other family endures a loss like this." "We ask that you keep the Carrs in your thoughts and prayers and respect their privacy as they prepare to lay Jaysen to rest," Bailey Law Firm's statement said. Brain-eating amoeba: Person dies from Naegleria fowleri in South Carolina, officials say Family says boy was infected with brain-eating amoeba at SC lake The family's statement also said Jaysen Carr developed the infection after swimming at Lake Murray outside Columbia. The SCDPH said it also believed the exposure occurred at the lake. "We cannot be completely certain as this organism occurs naturally and is present in many warm water lakes, rivers and streams," the agency said. What is Naegleria fowleri? Why is it known as a brain-eating amoeba? Naegleria fowleri is a type of amoeba that can cause a rare but nearly always fatal brain infection. It thrives in warm freshwater lakes, rivers and hot springs, according to the Centers for Disease Control and Prevention. The amoeba is often referred to as brain-eating because it can cause an infection called primary amebic meningoencephalitis (PAM) that destroys brain tissue. Most people who have been in bodies of waters have been exposed to the amoeba, but contact alone is not harmful, Dr. Anna Kathryn Burch, a pediatric infectious disease specialist at Prisma Health Children's Hospital Midlands, said during a news conference on July 22. "Where it can cause an issue is if forceful water gets up the nose and is able to cross from the nose into the brain," Burch said, adding that a PAM infection causes the brain to swell. To protect against a possible infection, the CDC recommends holding or wearing a nose clip when jumping into fresh water, keeping the head above water in hot springs and using distilled or boiled tap water when rinsing sinuses. Melina Khan is a national trending reporter for USA TODAY. She can be reached at
Newsweek
18 minutes ago
- Newsweek
Smart Speakers Like Alexa and Google Assistant Could Tell if You Have Parkinson's
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new AI-powered, speech-based screening tool could help people assess whether they are showing signs of Parkinson's disease at home. Developed as part of a study by University of Rochester computer scientists, the web-based test asks users to recite two pangrams, short sentences using every letter of the alphabet. In just seconds, the AI can analyze the voice recordings to look for subtle patterns linked to Parkinson's—with nearly 86 percent accuracy. The researchers believe such a tool could be implemented as a feature in popular speech-based interfaces like Amazon Alexa or Google Home (with users consent). Parkinson's is typically diagnosed by specially trained neurologists through a combination of examinations, brain imaging and family history. While the new tool is not intended to be a replacement for a clinical diagnosis, the researchers see it as a fast, low-barrier and accessible way to flag people who might have the disease and encourage them to seek thorough clinical evaluation. Man connecting Alexa-like device to phone at home. Man connecting Alexa-like device to phone at 1.1 million people in the U.S. are living with Parkinson's disease, expected to rise to 1.2 million by 2030, according to Parkinson's Foundation. Nearly an estimated 90,000 people are diagnosed across the country each year, making it the second-most common neurodegenerative disease after Alzheimer's. While incidence increases with age, some four percent of people are diagnosed before 50. "There are huge swaths of the U.S. and across the globe where access to specialized neurological care is limited," said Rochester computer science professor Ehsan Hoque in a statement. "With users' consent, widely used speech-based interfaces like Amazon Alexa or Google Home could potentially help people identify if they need to seek further care." Most people living with Parkinson's in the U.S. seek their care from neurologists, with approximately 50 percent seeing a community neurologist and 9 percent seeing a movement disorders specialist, a previous Parkinson's Foundation study found. However, nearly 40 percent of people with the disease do not see a neurologist for their care but see a primary care provider (29 percent) or no provider (11 percent.) Home speaker device. Home speaker device. fabioderby/Getty Images To train and validate the new tool the researchers collected data from more than 1,300 participants—with and without Parkinson's—across home care settings, clinical settings at the University of Rochester Medical Center and the InMotion Parkinson's disease care center in Ohio. Using their computer's microphone, participants were asked to read aloud the following sentences: "The quick brown fox jumps over the lazy dog. The dog wakes up and follows the fox into the forest, but again the quick brown fox jumps over the lazy dog." By utilizing advanced semi-supervised audio models trained on millions of digital recordings to understand the characteristics of speech, the tool can obtain enough vocal cues from the short sentences to flag warning signs. "For example, the way someone with Parkinson's would utter sounds, pause, breathe, and inadvertently add features of unintelligibility is different in someone without Parkinson's," explained paper author and computer science master's degree student Abdelrahman Abdelkader in a statement. The tool was 85.7 percent accurate when tested, providing a strong indication of whether someone may have Parkinson's, according to the study authors. Woman using Google Nest-like device at home. Woman using Google Nest-like device at well as speech, some people can display signs of Parkinson's through motor movement tasks or facial expressions. Over the past decade, this has led Hoque's lab to pursue algorithms to combine multiple indicators with state-of-the-art results. "Research shows that nearly 89 percent of people with Parkinson's have a deformity in their voice that can be indicative of the disease, making speech a strong starting point for digital screening," said paper author and computer scientist Tariq Adnan in a statement. "By combining this method with assessments of other symptoms, we aim to cover the majority of people through our accessible screening process." An interactive, browser-based demonstration of the lab's three screening tests, including this new speech test, is available to try out at home here. Newsweek has reached out to the study authors for more information. Do you have a health story to share with Newsweek? Do you have a question about Parkinson's? Let us know via health@ References Adnan, T., Abdelkader, A., Liu, Z., Hossain, E., Park, S., Islam, M. S., & Hoque, E. (2025). A novel fusion architecture for detecting Parkinson's Disease using semi-supervised speech embeddings. Npj Parkinson's Disease, 11(1), 176. Pearson, C., Hartzman, A., Munevar, D., Feeney, M., Dolhun, R., Todaro, V., Rosenfeld, S., Willis, A., & Beck, J. C. (2023). Care access and utilization among medicare beneficiaries living with Parkinson's disease. Npj Parkinson's Disease, 9(1), 108.
Yahoo
21 minutes ago
- Yahoo
Centene's (NYSE:CNC) Q2 Sales Beat Estimates But Stock Drops 12.2%
Health coverage company Centene (NYSE:CNC) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 22.4% year on year to $48.74 billion. Its non-GAAP loss of $0.16 per share was significantly below analysts' consensus estimates. Is now the time to buy Centene? Find out in our full research report. Centene (CNC) Q2 CY2025 Highlights: Lower payments from the government, higher medical costs, more expensive care for Medicaid members Revenue: $48.74 billion vs analyst estimates of $43.67 billion (22.4% year-on-year growth, 11.6% beat) Adjusted EPS: -$0.16 vs analyst estimates of $0.23 (significant miss) Adjusted EBITDA: -$282 million vs analyst estimates of $91.23 million (-0.6% margin, significant miss) Operating Margin: -0.9%, down from 3.1% in the same quarter last year Free Cash Flow Margin: 3.2%, down from 5% in the same quarter last year Customers: 28 million, up from 27.94 million in the previous quarter Market Capitalization: $13.32 billion "We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory," said Chief Executive Officer of Centene, Sarah M. London. Company Overview Serving nearly 1 in 15 Americans through its government healthcare programs, Centene (NYSE:CNC) is a healthcare company that manages government-sponsored health insurance programs like Medicaid and Medicare for low-income and complex-needs populations. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, Centene's sales grew at a solid 14.2% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Centene's annualized revenue growth of 9.8% over the last two years is below its five-year trend, but we still think the results were respectable. Centene also reports its number of customers, which reached 28 million in the latest quarter. Over the last two years, Centene's customer base averaged 1.2% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Centene reported robust year-on-year revenue growth of 22.4%, and its $48.74 billion of revenue topped Wall Street estimates by 11.6%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and suggests its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Centene's operating margin might fluctuated slightly over the last 12 months but has generally stayed the same, averaging 1.5% over the last five years. This profitability was lousy for a healthcare business and caused by its suboptimal cost structure. Analyzing the trend in its profitability, Centene's operating margin might fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. This quarter, Centene's breakeven margin was down 4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Centene's flat EPS over the last five years was below its 14.2% annualized revenue growth. However, its operating margin didn't change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. In Q2, Centene reported EPS at negative $0.16, down from $2.42 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Centene's full-year EPS of $5.16 to shrink by 24.8%. Key Takeaways from Centene's Q2 Results We liked that Centene beat analysts' revenue expectations this quarter. On the other hand, EPS missed significantly due to lower payments from the government, higher medical costs, more expensive care for Medicaid members. Management called the results "disappointing" and are addressing the issues in the business. Shares traded down 12.2% to $23.51 immediately following the results. Is Centene an attractive investment opportunity at the current price? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
